Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10900491 | 0.79 | CTSA (0.46) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL9112694 | 0.74 | CTSA (0.46) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3975395 | 0.72 | CTSA (0.43) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL9614591 | 0.72 | CTSA (0.43) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL4895468 | 0.70 | CTSA (0.42) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL11428726 | 0.69 | CTSA (0.36) | CTSAACHE | |
| SCHEMBL11049085 | 0.69 | CTSA (0.41) | CTSAACHE | |
| SCHEMBL31468710 | 0.69 | — | — | |
| SCHEMBL29005724 | 0.69 | CTSA (0.46) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL19038877 | 0.69 | CTSA (0.40) | CTSAACHEALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0200980-B1 | A PROCESS FOR HYDROLYZING SUBSTITUTED METHYLENEDIPHOSPHONIC ACID ESTERS | ISTITUTO GENTILI S.p.A. (IT) | 1990-01-31 | — | — | EP | claimed |
| EP-0200980-A1 | A process for hydrolyzing substituted methylenediphosphonic acid esters | ISTITUTO GENTILI S.p.A. (IT) | 1986-11-12 | — | — | EP | claimed |
| US-7994304-B2 | Sequencing nucleic acid molecules; promote accurate base-over-base incorporation in sequencing-by-synthesis reactions, resulting in greater read lengths | HELICOS BIOSCIENCES CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-20080227970-A1 | Methods And Compositions For Sequencing A Nucleic Acid | HELICOS BIOSCIENCES CORPORATION (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227970-A1 | Methods And Compositions For Sequencing A Nucleic Acid | HELICOS BIOSCIENCES CORPORATION (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080103053-A1 | Methods and compositions for sequencing a nucleic acid | HELICOS BIOSCIENCES CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103053-A1 | Methods and compositions for sequencing a nucleic acid | HELICOS BIOSCIENCES CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6255518-B1 | Preparation of fluorinated compounds | F2 CHEMICALS, LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| EP-1001918-A1 | PREPARATION OF FLUORINATED COMPOUNDS | F2 Chemicals Limited (GB) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999005080-A1 | PREPARATION OF FLUORINATED COMPOUNDS | F2 CHEMICALS LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | CTSA 3474/4885ACHE 3755/4885ALDH1A1 2112/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | CTSA 3474/4885ACHE 3755/4885ALDH1A1 2112/4885 |
| US-20080227970-A1 | Methods And Compositions For Sequencing A Nucleic Acid | RNGTT, NT5C3B, POLN | CTSA 4719/4885ACHE 4871/4885ALDH1A1 4557/4885 |
| US-20080103053-A1 | Methods and compositions for sequencing a nucleic acid | RNGTT, NT5C3B, POLN | CTSA 4719/4885ACHE 4871/4885ALDH1A1 4557/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | CTSA 3474/4885ACHE 3755/4885ALDH1A1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.